Swedish Orphan Biovitrum Logo

Swedish Orphan Biovitrum

Develops innovative therapies for rare diseases in haematology, immunology, and specialty care.

SOBI | ST

Overview

Corporate Details

ISIN(s):
SE0000872095 (+51 more)
LEI:
549300124Y3MQI87PT35
Country:
Sweden
Address:
Tomtebodavagen 23A, 112 76 Stockholm
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Swedish Orphan Biovitrum (Sobi) is a global biopharmaceutical company dedicated to developing and delivering innovative therapies for people with rare and debilitating diseases. The company focuses its research, development, and commercialization efforts on treatments in the areas of haematology, immunology, and specialty care. Sobi leverages its expertise in protein biochemistry and biologics manufacturing to address significant unmet medical needs. The company is committed to improving patient lives by providing sustainable access to transformative treatments for rare disease communities worldwide.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-21 13:00
Regulatory News Service
Förändring i Sobis styrelse
Swedish 132.4 KB
2025-10-21 13:00
Board/Management Information
Change in the Sobi Board of Directors
English 98.8 KB
2025-10-20 08:00
Quarterly Report
Swedish 3.8 MB
2025-10-20 08:00
Quarterly Report
English 4.1 MB
2025-10-19 20:30
Earnings Release
Sobi meddelar reviderade helårsutsikter och tidigarelägger publiceringen av del…
Swedish 206.4 KB
2025-10-19 20:30
Earnings Release
Sobi announces revised full year outlook and advances publication of the Q3 202…
English 174.2 KB
2025-09-30 08:00
Declaration of Voting Results & Voting Rights Announcements
New number of shares and votes in Sobi
English 137.5 KB
2025-09-30 08:00
Declaration of Voting Results & Voting Rights Announcements
Ändring av antalet aktier och röster i Sobi
Swedish 126.9 KB
2025-08-29 08:00
Declaration of Voting Results & Voting Rights Announcements
Ändring av antalet aktier och röster i Sobi
Swedish 100.2 KB
2025-08-29 08:00
Declaration of Voting Results & Voting Rights Announcements
New number of shares and votes in Sobi
English 97.9 KB
2025-08-21 12:35
Share Issue/Capital Change
Sobi has completed issues of class C shares
English 151.8 KB
2025-08-21 12:35
Share Issue/Capital Change
Sobi har genomfört emissioner av C-aktier
Swedish 151.6 KB
2025-07-16 08:00
Quarterly Report
Swedish 4.1 MB
2025-07-16 08:00
Earnings Release
English 4.1 MB
2025-07-15 19:15
Share Issue/Capital Change
The Board of Directors of Sobi exercises authorisation for repurchase of shares…
English 138.4 KB

Automate Your Workflow. Get a real-time feed of all Swedish Orphan Biovitrum filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Swedish Orphan Biovitrum

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Swedish Orphan Biovitrum via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2024-08-30 Katy Mazibuko Other Sell 1,500 480,000.00 SEK
2024-08-30 Katy Mazibuko Other Sell 269 86,012.75 SEK
2024-08-12 Sara Karlsson Other Buy 86 23,391.79 SEK
2024-07-25 Mahmood Ladha Other Buy 84,585 12,360,406.05 SEK
2024-07-23 Mahmood Ladha Other Sell 84,585 24,614,235.00 SEK
2024-06-10 Christin Wesström Other Other 7,433 N/A
2024-06-03 Guido Oelkers Other Buy 117,332 23,965,061.00 SEK
2024-05-30 Guido Oelkers Other Sell 117,332 32,090,302.00 SEK
2024-05-15 Henrik Stenqvist Other Buy 72,534 14,815,069.50 SEK
2024-05-13 Henrik Stenqvist Other Sell 72,534 20,766,484.20 SEK

Peer Companies

AIM ImmunoTech Inc. Logo
Develops immuno-therapeutics for cancers, immune disorders, and viral diseases.
United States of America
AIM
AKANDA CORP. Logo
Cultivates and distributes pharma-quality medical cannabis for patients in legal markets worldwide.
United States of America
AKAN
Akari Therapeutics Plc Logo
A clinical-stage oncology company developing next-gen ADCs for targeted cancer therapy.
United States of America
AKTX
Akebia Therapeutics, Inc. Logo
Developing and commercializing novel, FDA-approved therapeutics for kidney disease.
United States of America
AKBA
Akero Therapeutics, Inc. Logo
A clinical-stage biotech developing therapies for serious metabolic diseases like MASH.
United States of America
AKRO
Alaunos Therapeutics, Inc. Logo
Developing TCR-T cell therapies to treat solid tumors by targeting specific cancer mutations.
United States of America
TCRT
Aldeyra Therapeutics, Inc. Logo
Biotech developing therapies for ocular and systemic immune-mediated inflammation.
United States of America
ALDX
Alector, Inc. Logo
Pioneers immuno-neurology therapies for neurodegenerative diseases like Alzheimer's.
United States of America
ALEC
Aligos Therapeutics, Inc. Logo
Clinical-stage biopharma developing novel oral therapies for liver and viral diseases.
United States of America
ALGS
ALK-Abelló Logo
Develops allergy immunotherapy (AIT) and emergency treatments for severe allergies.
Denmark
ALK

Talk to a Data Expert

Have a question? We'll get back to you promptly.